Learning objectives
By the end of the week you can:
- Explain OEM economics segment by segment from the cost structure up: why two-wheelers earn 14–18% EBITDA margins, passenger vehicles 8–13%, and commercial vehicles 8–11% through a cycle. Then predict which way each band breaks when volumes, mix, discounts, or raw materials move.
- Detect channel stuffing with public data: reconcile an OEM's reported (wholesale) volumes against VAHAN/FADA retail registrations, convert the gap into channel inventory days, read rising discounts per unit as the corroborating flag, and quantify the operating-leverage hit when the destocking quarter arrives.
- Read the auto demand cycle as three engines: replacement demand, first-time buyers, and financing availability. Apply the segment-specific versions (freight economics for CV, penetration and model cycles for PV, rural cash flows for 2W), including how to read PV/CV order backlogs honestly.
- Assess the EV transition without cheerleading or denial: per-vehicle economics (battery cost, contribution margin), the cash-burn-versus-optionality trade, what "EV mix" does and does not tell you, and the Tesla-versus-Toyota lesson about integration, distribution, and margin durability.
- Analyze an auto ancillary as
revenue = industry volume × content per vehicle × share. Compute kit-value growth, judge OEM/client concentration and the aftermarket/OEM/export mix, model the RM pass-through lag quarter by quarter, apply the ROCE discipline test, and classify a component portfolio as ICE-at-risk, EV-agnostic, or EV-upside. - Explain the order-book business model (book → execute → collect) and run its KPI panel: order inflow, backlog, book-to-bill (>1× = growing), backlog coverage (EPC ~2.5–3.5× revenue), execution/burn rate, capacity utilization (>80% = pricing power), fixed-asset turns, and ROCE against the ~12% hurdle.
- Show with numbers why EPC companies die of working capital, not P&L: receivables, unbilled revenue (contract assets), retention money, and the bank-guarantee transmission channel. Then contrast the product model (Siemens/ABB-style, customer advances, negative working capital) with the project model (L&T-style) and a US product-plus-dealer anchor (Caterpillar-style).
- Choose the right valuation lens: EV/EBITDA and EV/EBIT on mid-cycle earnings for anything cyclical, P/E only for franchise-grade compounders within these sectors, never a trailing P/E at a cycle peak. Separate captive-finance books from industrial economics before computing any multiple.
Prerequisites & connections
Builds on. M1.06–M1.08 (inventory, revenue recognition: you will now meet over-time/percentage-of-completion revenue in the wild, and the R&D-capitalization comparability trap); M2.03–M2.05 (working-capital days, cash conversion, CFO/EBITDA, the core forensic toolkit both playbooks run on); M2.06 (channel stuffing as a shenanigan family, which here gets a sector-specific public-data detector); M3.07–M3.08 (multiples discipline and mid-cycle normalization); M4.03 (Five Forces, which you will run on the brutal PV industry and the cozy 2W duopoly-plus); M4.06 (the capital cycle: capacity addition at the top is the industrials disease).
Feeds into. M5.09 (commodities: the same cycle logic with zero pricing power; metals are these companies' raw materials, so the RM-lag mechanics carry straight over); M5.10 (the cross-sector multiples map, to which autos and industrials supply the cyclical column); Phase 8 (the rapid teardown of any manufacturer leans entirely on these KPI panels); Phase 9 (position sizing for cyclicals: why you size on mid-cycle value, not peak earnings momentum).
The one-line bridge from M5.07. Pharma sold molecules with patent clocks; autos and industrials sell metal with demand clocks. In both, the reported quarter tells you almost nothing without knowing where you are on the clock.
4.1 Two families, one disease: deferrable demand
Start with the customer, as always. Nobody must buy a new truck this year. A fleet operator can run his truck a ninth year; a family can keep the old hatchback; a factory can sweat its machines; a state government can delay the highway tender. Nobody defers insulin, which is what last week's businesses were selling. Out of that difference comes the single most important sentence you will read all week:
When purchases are deferrable and financed, demand doesn't decline in a downturn — it disappears.
A 5% fall in GDP growth does not produce a 5% fall in truck sales; it produces a 30–50% fall, because everyone defers at once, and the people who wouldn't have deferred can't get financing. Symmetrically, recoveries are violent: three years of deferred replacement arrives in eighteen months. Layer on high fixed costs (plants, dealer networks, engineering staff) and you get operating leverage: margins expand ferociously on the way up and evaporate on the way down. A business with 25% contribution margin and heavy fixed costs can swing from 14% EBITDA margin to 2% on a 30% volume decline. No fraud, no mismanagement, just arithmetic.